On the remarkable antitumor properties of fludelone: How we got there

Angewandte Chemie - International Edition

Volumn 44, Issue 19, 2005, Pages 2838-2850

  Rivkin, Alexey ^a,c   Chou, Ting Chao ^a,d   Danishefsky, Samuel J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Anticancer drugs; Drug development; Epothilones; Natural products; Total synthesis

Indexed keywords

BIOMOLECULES; CLINICAL VALUE; EPOTHILONES; FLUDELONE;

BIOSYNTHESIS; MOLECULAR STRUCTURE; PROTEINS;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; FLUDELONE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; MOUSE; SHORT SURVEY; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; EPOTHILONES; HUMANS; MICE; MOLECULAR STRUCTURE;

EID: 18844378165     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200461751     Document Type: Short Survey

References (102)

1. S. F. Brady, C. J. Chao, J. Clardy, J. Am. Chem. Soc. 2002, 124, 9968.
2. a) V. Knight, J. J. Sanglier, D. DiTullio, S. Braccili, P. Bonner, J. Waters, D. Hughes, L. Zhang, Appl. Microbiol. Biotechnol. 2003, 62, 446;
3. b) D. J. Newman, G. M. Cragg, K. M. Snader, Nat. Prod. Rep. 2000, 17, 215.
4. a) D. C. Myles, Curr. Opin. Biotechnol. 2003, 14, 627;
5. b) Y.-Z. Shu, J. Nat. Prod. 1998, 61, 1053;
6. c) L. A. Wessjohann, Curr. Opin. Chem. Biol. 2000, 4, 303;
7. d) D. J. Newman, G. M. Cragg, K. M. Snader, J. Nat. Prod. 2003, 66, 1022.
8. A. G. Ravelo, A. Estevez-Braun, H. Chavez-Orellana, E. Perez-Sacau, D. Mesa-Siverio, Curr. Top. Med. Chem. 2004, 2, 241, and references therein.
9. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggan, A. T. McPhail, J. Am. Chem. Soc. 1971, 93, 2325.
10. a) P. B. Schiff, S. B. Horwitz, Proc. Natl. Acad. Sci. USA 1980, 77, 1561;
11. b) P. B. Schiff, S. B. Horwitz, Nature 1979, 277, 665;
12. c) J. Parness, S. B. Horwitz, J. Cell Biol. 1981, 91, 479;
13. d) K. C. Nicolaou, W.-M. Dai, R. K. Guy, Angew. Chem. 1994, 106, 38
14. Angew. Chem. Int. Ed. Engl. 1994, 33, 15;
15. e) E. K. Rowinsky, Annu. Rev. Med. 1997, 48, 353.
16. D. Guenard, F. Gueritte-Vogelein, P. Potier, Acc. Chem. Res. 1993, 26, 160.
17. S. J. Danishefsky, J. J. Masters, W. B. Young, J. T. Link, L. B. Snyder, T. V. Magee, D. K. Jung, R. C. A. Isaacs, W. G. Bornmann, C. A. Alaimo, C. A. Coburn, M. J. DiGrandi, J. Am. Chem. Soc. 1996, 118, 2843.
18. a) K. C. Nicolaou, Z. Yang, J. J. Liu, H. Ueno, P. G. Nantermet, R. K. Guy, C. F. Claiborne, J. Renaud, E. A. Couladouros, K. Paulvannan, E. J. Sorenson, Nature 1994, 367, 630;
19. b) K. C. Nicolaou, P. G. Nantermet, H. Ueno, R. K. Guy, E. A. Couladouros, E. J. Sorenson, J. Am. Chem. Soc. 1995, 117, 624;
20. c) K. C. Nicolaou, J. J. Liu, Z. Yang, H. Ueno, E. J. Sorenson, C. F. Claiborne, R. K. Guy, C. K. Hwang, M. Nakada, P. G. Nantermet, J. Am. Chem, Soc. 1995, 117, 634;
21. d) K. C. Nicolaou, Z. Yang, J. J. Liu, P. G. Nantermet, C. F. Claiborne, J. Renaud, R. K. Guy, K. Shibayama, J. Am. Chem. Soc. 1995, 117, 645;
22. e) K. C. Nicolaou, H. Ueno, J. J. Liu, P. G. Nantermet, Z. Yang, J. Renaud, K. Paulvannan, R. Chadha, J. Am. Chem. Soc. 1995, 117, 653.
23. a) R. A. Holton, C. Somoza, H. B. Kim, F. Liang, R. J. Biediger, P. D. Boatman, M. Shindo, C. C. Smith, S. C. Kim, H. Nadizadeh, Y. Suzuki, C. L. Tao, P. Vu, S. H. Tang, P. S. Zhang, K. K. Murthi, L. N. Gentile, J. H. Liu, J. Am. Chem. Soc. 1994, 116, 1597;
24. b) R. A. Holton, H. B. Kim, C. Somoza, F. Liang, R. J. Biediger, P. D. Boatman, M. Shindo, C. C. Smith, S. C. Kim, H. Nadizadeh, Y. Suzuki, C. L. Tao, P. Vu, S. H. Tang, P. S. Zhang, K. K. Murthi, L. N. Gentile, J. H. Liu, J. Am. Chem. Soc. 1994, 116, 1599.
25. a) E. K. Rowinsky, E. A. Eisenhauer, V. Chaudhry, S. G. Arbuck, R. C. Donehawer, Semin. Oncol. 1993, 20, 1;
26. b) B. S. Fletcher, D. A. Kujubadu, D. M. Perrin, H. R. Herschman, J. Biol. Chem. 1992, 267, 4338;
27. c) M. Tsuji, R. N. Dubois, Cell, 1995, 3, 493;
28. d) D. M. Essayan, A. Kagey-Sobotka, P. J. Colarusso, L. M. Lichtenstein, R. F. Ozols, E. D. King, J. Allergy Clin. Immunol. 1996, 97, 42;
29. e) P. Giannakakou, D. L. Sackett, Y.-K. Kang, Z. Zhan, J. T. Buters, T. Fojo, M. S. Poruchynsky, J. Biol. Chem. 1997, 272, 17118, and references therein.
30. G. Höfle, N. Bedorf, K. Gerth, H. Reichenbach (GBF), DE-B 4138042 ,1993; Chem. Abstr. 1993, 120, 52841.
31. D. M. Bollag, P. A. McQueney, J. Zhu, O. Hensens, L. Koupal, J. Liesch, M. Goetz, E. Lazarides, C. M. Woods, Cancer Res. 1995, 55, 2325. We thank Professor Gunda Georg of the University of Kansas for calling this publication to our attention, and Dr. D. M. Bollag of Merck Sharp and Dohme for providing us with about 1 mg of epothilone A to commence studies (ultimately unsuccessful) towards the determination of its configuration.
32. a) See reference [12] ;
33. b) R. J. Kowalski, E. Terhaar, R. E. Longley, S. P. Gunasekera, C. M. Lin, B. V. Day, E. Hamel, Mol. Biol. Cell 1995, 6, 2137;
34. c) E. K. Rowinsky, E. A. Eisenhauer, V. Chaudhry, S. G. Arbuck, R. C. Donehawer, Semin. Oncol. 1993, 20, 1;
35. d) B. S. Fletcher, D. A. Kujubadu, D. M. Perrin, H. R. Herschman, J. Biol. Chem. 1992, 267, 4338;
36. e) M. Tsuji, R. N. Dubois, Cell 1995, 3, 493;
37. f) D. M. Essayan, A. Kagey-Sobotka, P. J. Colarusso, L. M. Lichtenstein, R. F. Ozols, E. D. King, J. Allergy Clin. Immunol. 1996, 97, 42;
38. g) P. Giannakakou, D. L. Sackett, Y.-K. Kang, Z. Zhan, J. T. Buters, T. Fojo, M. S. Poruchynsky, J. Biol. Chem. 1997, 272, 17118, and references therein.
39. G. H. Höfle, N. Bedorf, H. Steinmetz, D. Schomburg, K. Gerth, H. Reichenbach, Angew. Chem. 1996, 108, 1671;
40. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567.
41. a) A. Balog, D. F. Meng, T. Kamenecka, P. Bertinato, D.-S. Su, E. J. Sorensen, S. J. Danishefsky, Angew. Chem. 1996, 108, 2976;
42. Angew. Chem. Int. Ed. Engl. 1996, 35, 2801;
43. b) D.-S. Su, D. F. Meng, P. Bertinato, A. Balog, E. J. Sorensen, S. J. Danishefsky, Y. H. Zheng, T.-C. Chou, L. F. He, S. B. Horwitz, Angew. Chem. 1997, 109, 775;
44. Angew. Chem. Int. Ed. Engl. 1997, 36, 757;
45. c) D. F. Meng, P. Bertinato, A. Balog, D.-S. Su, T. Kamenecka, E. J. Sorensen, S. J. Danishefsky, J. Am. Chem. Soc. 1997, 119, 10073.
46. a) A. Rivkin, F. Yoshimura, A. E. Gabarda, T.-C. Chou, H. Dong, W. P. Tong, S. J. Danishefsky, J. Am. Chem. Soc. 2003, 125, 2899;
47. b) T.-C. Chou, H. Dong, A. Rivkin, F. Yoshimura, A. E. Gabarda, Y. S. Cho, W. P. Tong, S. J. Danishefsky, Angew. Chem. 2003, 115, 4910;
48. Angew. Chem. Int. Ed. 2003, 42, 4761;
49. c) F. Yoshimura, A. Rivkin, A. E. Gabarda, T.-C. Chou, H. Dong, G. Sukenick, S. J. Danishefsky, Angew. Chem. 2003, 115, 2622;
50. Angew. Chem. Int. Ed. 2003, 42, 2518.
51. In an early RCM-based approach studied in our laboratory, the 12,13-epoxide was already in place. We also investigated RCM to reach the 12,13-alkene, but only in the context of surveying various possibilities. For reviews of RCM, see: a) R. H. Grubbs, S. J. Miller, G. C. Fu, Acc. Chem. Res. 1995, 28, 446;
52. b) T. M. Trinka, R. H. Grubbs, Acc. Chem. Res. 2001, 34, 18;
53. c) A. Fürstner, Alkene Metathesis in Organic Chemistry, Springer, Berlin, 1998;
54. d) A. Fürstner, Angew. Chem. 2000, 112, 3140;
55. Angew. Chem. Int. Ed. 2000, 39, 3012;
56. e) R. R. Schrock, Top. Organomet. Chem. 1998, 1, 1.
57. See reference [16c] and A. Rivkin, Y. S. Cho, A. E. Gabarda, Y. Fumihiko, S. J. Danishefsky, J. Nat. Prod. 2004, 67, 139.
58. C. R. Harris, S. J. Danishefsky, J. Org. Chem. 1999, 64, 8434, and references therein.
59. a) S. J. Danishefsky, Aldrichimica Acta 1986, 19, 59;
60. b) S. J. Danishefsky, Chemtracts 1989, 2, 273.
61. Naturally, when we conceived this remarkable aldolization we were aware of the non-enolizability of the "C3" aldehyde in the C2-C3 seco structure.
62. S. J. Stachel, S. J. Danishefsky, Tetrahedron Lett. 2001, 42, 6785.
63. See reference [16a]. Shortly after our synthesis, two other efforts, each exploiting olefin metathesis, were described: a) Z. Yang, Y. He, D. Vourloumis, H. Vallberg, K. C. Nicolaou, Angew. Chem. 1997, 109, 170;
64. Angew. Chem. Int. Ed. Engl. 1997, 36, 166;
65. b) D. Schinzer, A. Limberg, A. Bauer, O. Böhm, M. Cordes, Angew. Chem. 1997, 109, 543;
66. Angew. Chem. Int. Ed. Engl. 1997, 36, 523.
67. For the first SAR (structure-activity relationship) map, see: a) D.-S. Su, A. Balog, D. Meng, P. Bertinato, S. J. Danishefsky, Y.-H. Zheng, T.-C. Chou, L. He, S. B. Horwitz, Angew. Chem. 1997, 109, 2178;
68. Angew. Chem. Int. Ed. Engl. 1997, 36, 2093;
69. see also: b) K. C. Nicolaou, D. Vourloumis, T. Li. , J. Pastor, N. Winssinger, Y. He, S. Ninkovic, F. Sarabia, H. Vallberg, F. Roschanger, N. P. King, M. Ray, V. Finlay, P. Giannakakou, P. Verdier-Pinard, E. Hamel, Angew. Chem. 1997, 109, 2181;
70. Angew. Chem. Int. Ed. Engl. 1997, 36, 2097;
71. for the earliest in vivo assays of dEpoB, see: c)T.-C. Chou, X. G. Zhang, C. R. Harris, S. D. Kuduk, A. Balog, K. A. Savin, J. R. Bertino, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 1998, 95, 15 798;
72. d) T.-C. Chou, X. G. Zhang, A. Balog, D. Su, D. F. Meng, K. Savin, J. R. Bertino, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 1998, 95, 9642;
73. e) T.-C. Chou, O. A. O'Connor, W. P. Tong, Y. Guan, Z.-G. Zhang, S. J. Stachel, C. Lee, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 2001, 98, 8113.
74. Novartis is the sponsor of the clinical trials with EpoB. For EpoB preclinical data reported by Novartis, see: a) K.-H. Altmann, M. Wartmann, T. O'Reilly, Biochim. Biophys. Acta 2000, 1470, M79;
75. b) J. Rothermel, M. Wartmann, T. Chen, J. Hohneker, Semin. Oncol. 2003, 6(Suppl.30), 51.
76. C. R. Harris, S. D. Kuduk, A. Balog, K. Savin, P. W. Glunz, S. J. Danishefsky, J. Am. Chem. Soc. 1999, 121, 7051.
77. N.-H. Lin, L. E. Overman, M. H. Rabinowitz, L. A. Robinson, M. J. Sharp, J. Zablocki, J. Am. Chem. Soc. 1996, 118, 9062.
78. D. A. Evans, J. V. Nelson, T. R. Taber, Top. Stereochem. 1982, 13, 1.
79. R. Noyori, T. Ohkuma, M. Kitamura, H. Takaya, N. Sayo, H. Kumobayahshi, S. Akutagawa, J. Am. Chem. Soc. 1987, 109, 5856.
80. Bristol-Myers Squibb (BMS) is sponsoring clinical trials of the 15-desoxy-15-aza congener: a) R. M. Borzilleri, X. Zheng, R. J. Schmidt, J. A. Johnson, S.-H. Kim, J. D. DiMarco, C. R. Fairchild, J. Z. Gougoutas, F. Y. F. Lee, B. H. Long, G. D. Vite, J. Am. Chem. Soc. 2000, 122, 8890;
81. b) F. Y. F. Lee, R. Borzilleri, C. R. Fairchild, S.-H Kim, B. H. Long, C. Reventos-Suarez, G. D. Vite, W. C. Rose, R. A. Kramer, Clin. Cancer Res. 2001, 7, 1429;
82. BMS is also sponsoring clinical trials of another epothilone derivative (BMS310705): c) R. M. Borzilleri, G. D. Vite, Drugs Future 2002, 27, 1149.
83. L. Tang, S. Shah, L. Chung, J. Carney, L. Katz, C. Khosla, B. Julien, Science 2000, 287, 640.
84. For more information about the clinical trials of dEpoB, visit: www.kosan.com.
85. R. L. Arslanian, L. Tang, S. Blough, W. Ma, R. G. Qiu, L. Katz, J. R. Carn, J. Nat. Prod. 2002, 65, 570.
86. M. D. Chappell, S. J. Stachel, C. B. Lee, S. J. Danishefsky, Org. Lett. 2000, 2, 1633.
87. K. Biswas, H. Lin, J. T. Njardarson, M. D. Chappell, T.-C. Chou, Y. Guan, W. P. Tong, L. He, S. B. Horwitz, S. J. Danishefsky, J. Am. Chem. Soc. 2002, 124, 9825.
88. a) B. E. Smart, J. Fluorine Chem. 2001, 109, 3;
89. b) I. Ojima, T. Inoue, S. Chakravarty, J. Fluorine Chem. 1999, 97;
90. c) R. A. Newman, J. Yang, M. R. V. Finlay, F. Cabral, D. Vourloumis, L. C. Stephens, P. Troncoso, X. Wu, C. J. Logothetis, K. C. Nicolaou, N. M. Navone, Cancer Chemother. Pharmacol. 2001, 48, 319;
91. d) Special issue on "Fluorine in the Life Sciences", ChemBioChem 2004, 5, 557-726.
92. A. Rivkin, K. Biswas, T.-C. Chou, S. J. Danishefsky, Org. Lett. 2002, 4, 4081.
93. Unpublished results.
94. A. Rivkin, J. T. Njardarson, K. Biswas, T.-C. Chou, S. J. Danishefsky, J. Org. Chem. 2002, 67, 7737.
95. K. C. Nicolaou, F. Sarabia, S. Ninkovic, M. Ray, V. Finlay, C. N. C. Boddy, Angew. Chem. 1998, 110, 85;
96. Angew. Chem. Int. Ed. Engl. 1998, 37, 81.
97. A. Rivkin, F. Yoshimura, A. E. Gabarda, Y. S. Cho, T.-C. Chou, H. Dong, S. J. Danishefsky, J. Am. Chem. Soc. 2004, 126, 10913.
98. J. D. White, R. G. Carter, K. F. Sundermann, M. Wartmann, J. Am. Chem. Soc. 2001, 123, 5407.
99. J. D. White, R. G. Carter, K. F. Sundermann, M. Wartmann, J. Am. Chem. Soc. 2003, 125, 3190.
100. For a recent and impressive case of long-term cure, see: M. J. Towle, K. A. Salvato, J. Budrow, B. F. Wels, G. Kuznetsov, K. K. Aalfs, S. Welsh, W. Zheng, B. M. Seletsky, M. H. Palme, G. J. Habgood, L. A. Singer, L. V. DiPietro, Y. Wang, J. J. Chen, D. A. Quincy, A. Davis, K. Yoshimatsu, Y. Kishi, M. J. Yu, B. A. Littlefield, Cancer Res. 2001, 61, 1013. Our case is particularly noteworthy in that the cures were established consistently. Furthermore, they were established on high tumor burdens, and the drug shows oral-administration efficacy.
101. R. Breinbauer, I. R. Vetter, H. Waldmann, Angew. Chem. 2002, 114, 3002;
102. Angew. Chem. Int. Ed. 2002, 41, 2878.